DKK-3 and WIF-1: Proteins related to liver cancer development?June 15, 2009Liver cancer is one of the most fatal human malignancies and the third most frequent cause of tumor-related death, about half a million people globally each year. The current methods used to monitor such high-risk groups include ultrasound scans and a test for the presence of a single protein in the blood called alpha-fetoprotein. It is a good indicator of advanced liver cancer, but less able to detect early disease. So it is the most impotent thing is find the changes of biomarker combinations in the early period of diseases, control the key gene in the initial stage of disease and reverse the development of disease. Wnt signal transduction pathway was significantly related to human neoplastic transformation. The Wnt-antagonist genes function as tumor suppressors and contribute to the pathogenesis of several human malignancies. Such as the promoter-hypermethylation and reduced expression of the DKK-3 gene was found in bladder cancer, lung cancer cell lines and tissues, the WIF-1 gene was found in lung cancer cell lines and tissues, malignant pleural mesothelioma cell lines and tissues, and nasopharyngeal cancer cell lines, also. A research article to be published on June 7, 2009 in the World Journal of Gastroenterology addresses this question. The study suggested the proteins transcripted by DKK-3 and WIF-1 can act as cancer-associated proteins relate with liver cancer development, but it isn't the same mechanism with hepatitis B (HBV) infection reducing the liver cancer development. The author identified that the silence of DKK-3 and WIF-1 gene resulted from the hypermethylation of its promoter maybe one of carcinogenic factors related to age and apart from HBV infection and the expression of DKK-3 is negatively related to the stage of tumor and cell proliferation. All of this suggested DKK-3 and WIF-1 have great potential to be identified as cancer-associated proteins in the liver cancer development. It may be provide a reliable way to improve liver cancer early diagnosis and new therapies by blocking this pathway to treatment of liver cancer through further study. World Journal of Gastroenterology |
|||||||||||||||||||||
| Related Liver Cancer Current Events and Liver Cancer News Articles Toward explaining why hepatitis B hits men harder than women Scientists in China are reporting discovery of unusual liver proteins, found only in males, that may help explain the long-standing mystery of why the hepatitis B virus (HBV) sexually discriminates -- hitting men harder than women. Largest-ever database for liver proteins may lead to treatments for hepatitis Scientists at a group of 11 research centers in China are reporting for the first time assembly of the largest-ever collection of data about the proteins produced by genes in a single human organ. 1 disease, not 1 demographic The Asian continent has nearly four billion people living in 47 different countries, and each of these groups has their own unique set of health issues. But when they come to the United States, they're often lumped into one large demographic: "Asian/Pacific Islander." Parasite growth hormone pushes human cells to liver cancer Scientists have found that the human liver fluke (Opisthorchis viverrini) contributes to the development of bile duct (liver) cancer by secreting granulin, a growth hormone that is known to cause uncontrolled growth of cells. Certain cancers more common among HIV patients than non-HIV patients Researchers at UT Southwestern Medical Center have found that non-AIDS-defining malignancies such as anal and lung cancer have become more prevalent among HIV-infected patients than non-HIV patients since the introduction of anti-retroviral therapies in the mid-1990s. Discovery could improve hepatitis C treatment Walter and Eliza Hall Institute researchers are part of an international team that has discovered a genetic variation that could identify those people infected with hepatitis C who are most likely to benefit from current treatments. Sorafenib significantly improves the length of time before breast cancer worsens ne of the first of a series of trials to investigate the use of sorafenib - a targeted anti-cancer drug - for the treatment of advanced breast cancer has found that if it is combined with the chemotherapy drug, capecitabine, it makes a significant difference to the time women live without their disease worsening. Penn State College of Medicine research isolates liver cancer stem cells prior to tumor formation Penn State College of Medicine researchers, in collaboration with colleagues at the University of Southern California, have taken an important step in understanding the role of stem cells in development of liver cancer. New biomarker predicts response to hepatitis C treatment Researchers have identified the first genetic marker that predicts response to hepatitis C treatments, and a single letter of DNA code appears to make a huge difference. Sequential TACE and cryosurgery can improve survival times for patients with HCC? Hepatocellular carcinoma (HCC)--a liver cancer--is recognized as one of the most common cancers in the world that disproportionately affects Southeast Asians and Africans. More Liver Cancer Current Events and Liver Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||